DistantNews
Support us
Samsung Biologics Eyes Europe with New Amsterdam Office
🇰🇷 South Korea /Economy & Trade

Samsung Biologics Eyes Europe with New Amsterdam Office

From Dong-A Ilbo · () Korean

Translated from Korean, summarized and contextualized by DistantNews.

At a glance

News Official statement New plan
  • Samsung Biologics will open a European sales office in Amsterdam in the third quarter, marking its first direct sales base on the continent.
  • The expansion aims to strengthen its presence in the major global biopharmaceutical markets of the US, Japan, and Europe.
  • The company is also increasing production capacity and exploring new markets like obesity treatments, while managing labor relations and integrating AI into operations.

Samsung Biologics is set to establish its first European sales office in Amsterdam during the third quarter, signaling a strategic push to directly target the continent's major biopharmaceutical market. This move follows the establishment of offices in the US and Japan, completing its global sales network across key regions.

We plan to open a sales office in Amsterdam in the third quarter.

— John RimSamsung Biologics CEO John Rim announcing the company's European expansion plans.

John Rim, CEO of Samsung Biologics, announced the plan during a press conference at the BIO International Convention in San Diego. The Amsterdam office, located near Schiphol Airport, is chosen for its central European location and accessibility from Korea. The company aims to increase face-to-face interactions with leading European pharmaceutical and biotech firms to boost contract orders.

It is the optimal sales base in the center of the European continent with high accessibility from Korea.

— John RimSamsung Biologics CEO John Rim describing the strategic location of the new Amsterdam office.

To support its global expansion, Samsung Biologics has also been enhancing its production capabilities. The acquisition of a manufacturing plant in Rockville, Maryland, in March increased its total global production capacity to 845,000 liters. This move is expected to be crucial in securing U.S. clients and leveraging both Korean and U.S. production bases.

With the acquisition of the Rockville plant, we can respond more closely to global customers and utilize both Korean and U.S. production bases together.

— John RimSamsung Biologics CEO John Rim on the benefits of the recent U.S. plant acquisition.

The company is also diversifying its service offerings beyond antibody-drug conjugates. It is closely monitoring the rapidly growing market for GLP-1-based obesity treatments, although this requires different production capabilities. Samsung Biologics is exploring new areas such as peptide and cell/gene therapies at its new Songdo bio-campus to adapt to evolving market demands. Meanwhile, Rim addressed ongoing labor negotiations, assuring clients that business disruptions are being minimized and that the company is proactively communicating the situation. He also highlighted the integration of Artificial Intelligence (AI) into operations to improve efficiency in production, quality control, and customer service.

We are considering business opportunities arising from the expansion of the obesity treatment market.

— John RimSamsung Biologics CEO John Rim discussing the company's interest in the growing obesity treatment sector.
DistantNews Editorial

Originally published by Dong-A Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog